4 October 2015 - The pCODR has recommended the listing of Iclusig (ponatinib hydrochloride) for patients with CML and Philadelphia chromosome positive ALL in whom the use of a tyrosine kinase inhibitor (TKI) is inappropriate, patients with a T351I mutation and patients with TKI resistance or intolerance.  The recommendation is conditional on its cost-effectiveness being improved to an acceptable level.

For more details, go to: https://www.cadth.ca/sites/default/files/pcodr/pcodr_ponatinib_iclusig_cml-all_fn_rec.pdf